Several brokerages have updated their recommendations and price targets on shares of Jade Biosciences (NASDAQ: JBIO) in the last few weeks:
- 6/2/2026 – Jade Biosciences was given a new $55.00 price target by Piper Sandler.
- 6/2/2026 – Jade Biosciences had its “buy” rating reaffirmed by Guggenheim. They now have a $47.00 price target on the stock.
- 6/2/2026 – Jade Biosciences had its price target raised by Wedbush from $34.00 to $45.00. They now have an “outperform” rating on the stock.
- 6/1/2026 – Jade Biosciences had its “buy” rating reaffirmed by Jefferies Financial Group Inc..
- 6/1/2026 – Jade Biosciences was upgraded by Weiss Ratings from “sell (d-)” to “sell (d)”.
- 6/1/2026 – Jade Biosciences had its price target raised by BTIG Research from $39.00 to $74.00. They now have a “buy” rating on the stock.
- 6/1/2026 – Jade Biosciences had its price target raised by HC Wainwright from $45.00 to $55.00. They now have a “buy” rating on the stock.
- 5/27/2026 – Jade Biosciences had its “buy” rating reaffirmed by BTIG Research. They now have a $39.00 price target on the stock.
- 5/11/2026 – Jade Biosciences was downgraded by Weiss Ratings from “sell (d)” to “sell (d-)”.
- 5/11/2026 – Jade Biosciences had its price target raised by Guggenheim from $23.00 to $32.00. They now have a “buy” rating on the stock.
- 5/11/2026 – Jade Biosciences had its price target raised by Wedbush from $24.00 to $34.00. They now have an “outperform” rating on the stock.
- 5/9/2026 – Jade Biosciences was downgraded by Wall Street Zen from “hold” to “sell”.
- 4/27/2026 – Jade Biosciences had its price target raised by HC Wainwright from $35.00 to $45.00. They now have a “buy” rating on the stock.
- 4/24/2026 – Jade Biosciences was upgraded by Weiss Ratings from “sell (d-)” to “sell (d)”.
- 4/10/2026 – Jade Biosciences had its “sell (d-)” rating reaffirmed by Weiss Ratings.
Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.
The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.
Read More
- Five stocks we like better than Jade Biosciences
- A Market Rotation Toward Quality Will Benefit These 3 ETFs
- 3 Multi-Metal Stocks for Income and Long-Term Growth
- Nebius Is Up Nearly 175% This Year—Here’s What’s Driving the Latest Run
- Technology Stocks Just Got Cheaper—Here Are 5 Mega-Caps Worth a Closer Look
Receive News & Ratings for Jade Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jade Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.
